Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Protalix Ltd.

Home Clinical Trial Sponsors and OrganizationsProtalix Ltd.

Protalix Ltd.

2 Snunit, Karmiel, Northern District, Israel

Also known as:

metabogal ltd

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

39

36 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

35

89.7%

Phase 3

2

5.1%

Trial Status Distribution

Active, not recruiting

36

92.3%

Completed

2

5.1%

Recruiting

1

2.6%

Clinical Trials

Trials sponsored by this organization (39)

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry Disease

Active, not recruiting

Sep 202140 participants

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease

Apr 2021110 participants

Phase 3 Study of the Safety, Efficacy & PK of pegunigalsidase alfa (PRX-102) 2 mg/kg IV Administered Every 4 Weeks in Fabry Disease Patients (BRIGHT)

Active, not recruiting

Nov 202030 participants

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease

Active, not recruiting

Oct 2020110 participants

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease

Active, not recruiting

Nov 2019110 participants

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry Disease

Active, not recruiting

Oct 201940 participants

Safety and effectiveness study comparing PRX-102 and Agalsidase Beta on Kidney function for patients with Fabry Disease who have previously been treated with Agalsidase Beta

Active, not recruiting

May 201978 participants

Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease

Active, not recruiting

Apr 2019110 participants

Page 1 of 5

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials39
Approvals
News

Back to Organizations